Core Insights - Emboline, Inc. has secured $20 million in growth capital from Trinity Capital to support the commercialization of its Emboliner® Embolic Protection System, aimed at minimizing stroke risk during transcatheter aortic valve replacement (TAVR) procedures [1][1][1] Company Overview - Emboline, Inc. is a privately held medical technology company based in Santa Cruz, California, focused on developing technologies to reduce embolic complications during transcatheter cardiovascular procedures [1][1] - The company's lead product, the Emboliner® Embolic Protection System, is designed to provide full cerebral and systemic embolic protection by capturing and removing debris released during structural heart interventions [1][1] Funding and Development - The funding from Trinity Capital will support Emboline's upcoming commercial launch activities and the continued development of its embolic protection technology platform [1][1] - Emboline has completed enrollment in the PROTECT H2H investigational device exemption (IDE) clinical trial, which evaluates the Emboliner® system [1][1] Clinical and Regulatory Milestones - Results from the completed IDE clinical study will be presented at the American College of Cardiology Annual Scientific Session on March 29, 2026 [1][1] - The financing positions Emboline to prepare for a commercial launch in the United States and Europe later this year [1][1] Strategic Partnerships - Trinity Capital, an international alternative asset manager, has a history of deploying over $5.5 billion across more than 463 investments since its inception in 2008, indicating a strong partnership for Emboline [1][1]